Meet the Affigen Team
Affigen’s founders are experts in immuno-oncology and mass-personalized bimolecular engineering, with deep expertise in oncology, manufacturing, regulatory affairs, genomics, bioinformatics, and clinical program development.
Collaborators and Scientific Advisors
We work closely with a number of collaborators that provide key research and process development components.
Our scientific advisors are key opinion leaders in immuno-oncology who helped design and develop the drugs which currently form the “standard of care” for a range of cancer classes to date.
Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry.
In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.